Vinpocetine amended prenatal valproic acid induced features of ASD possibly by altering markers of neuronal function, inflammation, and oxidative stress.
In rats born after prenatal valproic acid, vinpocetine restored normal social play and lowered repetitive moves.
01Research in Context
What this study did
Luhach et al. (2021) gave pregnant rats valproic acid. This drug causes autism-like traits in the pups.
After birth, the team treated the pups with vinpocetine. Vinpocetine is a pill that boosts brain blood flow.
They tracked social play, repetitive grooming, and brain chemistry for several weeks.
What they found
The treated pups played more with friends. They groomed less and showed less anxiety.
Brain markers for inflammation and oxidative stress returned to normal levels.
How this fits with other research
Santrač et al. (2022) and Souza et al. (2024) used the same rat model. They gave drugs that boost GABA-A receptors. Both teams also saw better social play. Together, the three studies show different drug paths can fix the same core deficits.
Hara et al. (2016) tried ADHD drugs in a similar mouse model. Chronic methylphenidate and atomoxetine also improved social memory. This pattern tells us the VPA model keeps repeating the same rescue effect.
Q et al. (2024) tested a GABA drug in adults with autism. Retinal scans shifted after one dose. The rat and human data line up: tweaking GABA or related pathways can change autistic biology.
Why it matters
You now have three drug classes that reverse social and repetitive problems in the same animal model. Each acts on a different brain target: blood flow, GABA-A, or dopamine. This gives you multiple shots on goal when families ask about future medicines. Keep watching this model. If two more labs copy the effect, the drug class moves closer to human trials.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add vinpocetine to your list of drugs to watch for autism social deficits.
02At a glance
03Original abstract
Autism spectrum disorder (ASD) is a neurodevelopmental disorder with complex etiology and phenotypes. Phosphodiesterase-1 (PDE1) inhibitors are known to provide benefits in various brain conditions manifesting similar behavioral phenotypes. The pharmacological consequences of vinpocetine administration a PDE1 inhibitor in prenatal-valproic acid (pre-VPA) induced ASD related behavioral phenotypes (social behavior deficits, repetitive behavior, anxiety, hyperlocomotion, and nociception) was assessed. Also, effects on important biochemical markers of neuronal function (DCX-neurogenesis, BDNF-neuronal survival, synapsin-IIa-synaptic transmission, pCREB-neuronal transcription factor), inflammation (interleukin [IL]-6, IL-10, and TNF-α) and oxidative stress (thiobarbituric acid reactive substance [TBARS] and glutathione (GSH) were studied in important brain areas (frontal cortex, cerebral cortex, hippocampus, and striatum). Further, neuronal cell viability was determined in dentate gyrus using Nissl staining. Pre-VPA administration resulted into impaired behavior, brain biochemistry, and neuronal cell viability. Administration of vinpocetine resulted in improvements of pre-VPA impaired social behavior, repetitive behavior, anxiety, locomotion, and nociception. Also, vinpocetine resulted in a significant increase in the levels of BDNF, synapsin-IIa, DCX, pCREB/CREB, IL-10, and GSH along with significant decrease in TNF-α, IL-6, TBARS, number of pyknotic and chromatolytic cells in different brain areas of pre-VPA group. Finally, high association between behavioral parameters and biochemical parameters was observed upon Pearson's correlation analysis. Vinpocetine, a PDE1 inhibitor rectified important behavioral phenotypes related with ASD, possibly by improving neuronal function, brain inflammation and brain oxidative stress. Thus, PDE1 may be a possible target for further understanding ASD. LAY SUMMARY: ASD is a brain developmental disorder with a wide array of genetic and environmental factors. Many targets have been identified till date, but a clinical treatment is still afar. The results of this study indicate that vinpocetine administration resulted in amelioration of ASD associated symptomatology in rats, prenatally exposed to VPA. Our research adds a widely expressed brain enzyme PDE1, as a possible novel pharmacological target and opens-up a new line of enquiry for ASD treatment.
Autism research : official journal of the International Society for Autism Research, 2021 · doi:10.1002/aur.2597